Compare MC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | KRYS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.3B |
| IPO Year | 2014 | 2017 |
| Metric | MC | KRYS |
|---|---|---|
| Price | $76.84 | $289.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $74.13 | ★ $244.20 |
| AVG Volume (30 Days) | ★ 699.6K | 294.0K |
| Earning Date | 02-04-2026 | 02-18-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 446.16 | 275.72 |
| EPS | 3.17 | ★ 6.66 |
| Revenue | ★ $1,467,580,000.00 | $373,164,000.00 |
| Revenue This Year | $27.41 | $36.14 |
| Revenue Next Year | $18.00 | $42.38 |
| P/E Ratio | ★ $24.20 | $42.93 |
| Revenue Growth | 51.19 | ★ 54.51 |
| 52 Week Low | $47.00 | $122.80 |
| 52 Week High | $82.89 | $295.98 |
| Indicator | MC | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 70.89 |
| Support Level | $74.57 | $271.52 |
| Resistance Level | $78.22 | $295.98 |
| Average True Range (ATR) | 2.65 | 12.15 |
| MACD | 0.06 | 1.56 |
| Stochastic Oscillator | 82.93 | 90.34 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.